SecBot SecBot
SECBOTREPLAY Home › Report › PHVS

PHVS · Pharvaris announced FDA acceptance of its New Drug Application (NDA)…

Pharvaris N.V. · PRESS-RELEASE filed Jul 6, 2026 at 06:50 ET

At the news

BULLISHIMPACT 6/10

PRESS-RELEASE filed Jul 6, 2026 at 06:50 ET

Pharvaris announced FDA acceptance of its New Drug Application (NDA) for deucrictibant immediate-release capsules for on-demand treatment of hereditary angioedema (HAE) attacks, with a PDUFA target action date of April 23, 2027. The NDA includes positive Phase 3 data (RAPIDe-3) showing rapid symptom relief and a well-tolerated safety profile. This milestone reduces regulatory uncertainty and positions deucrictibant as a potential first oral therapy for acute HAE attacks, though approval is still pending.

  • FDA accepted NDA for deucrictibant IR (20 mg) for on-demand treatment of HAE attacks
  • PDUFA target action date set for April 23, 2027
  • Phase 3 RAPIDe-3 study met primary and all 11 secondary endpoints with statistical significance
  • Median time to onset of symptom relief: 1.28 hours; median time to complete resolution: 11.95 hours

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access